MiR-26a can improve peripheral insulin sensitivity and protect β Cell function to alleviate type 2 diabetes [10], and miR-125a-5p can improve the disorder of hepatic glycolipid metabolism in type 2 diabetes by targeting signal transducer and activator of transcription 3 (STAT3) to inhibit hepatic adipogenesis and gluconeogenesis and increase glycogen synthesis [11]. The gene discussed is STAT3; the disease is type 2 diabetes mellitus.